INS and diabetes mellitus: We propose that currently emerging approaches [51] to provide treat-to-target insulin therapy during the pre-diabetic stage in order to suppress endogenous insulin production and ER-crowding, may benefit patients with pre-diabetes without significant rise in treatment related risk.